Dutch FF Pharma has a Promising Immunotherapy to fight Crohn’s Disease

05/08/2016 - 2 minutes

Arrivederci Italia! We’re going to fly up to the Netherlands for another Biotech-related adventure! This time, we’re visiting Utrecht, the fourth most populated city in the country and home-base to FF Pharma, our Biotech of the Week!

ff pharma logo

City: Utrecht (The Netherlands)

Founded: 2012

Employees: N/A

Financial Data: €4M Total Raised (as of 12/2015)

Related Content

CEO: Mark De Boer

mark de boer ceo ffpharma

Mission: FF Pharma focuses on the immune system, developing an antibody that targets CD40 – a major regulatory receptor. CD40 seems to play a big role in a variety of autoimmune diseases.

Its candidate is FFP104, currently in clinical development. The therapy is in a Phase I/II trial for Primary Biliary Cirrhosis (PBC), a rare disease where small bile ducts in the liver to become inflamed. Results from this study are expected soon, in the second half of 2016.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following: